Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial

Journal of Infectious Diseases

Volumn 176, Issue 5, 1997, Pages 1129-1134

  Straus, S E ^a   Wald, A ^b   Kost, R G ^b   McKenzie, R ^b   Langenberg, A G M ^b   Hohman, P ^b   Lekstrom, J ^b   Cox, E ^b   Nakamura, M ^b   Sekulovich, R ^b   Izu, A ^b   Dekker, C ^b   Corey, L ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; PLACEBO;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; FEMALE; GENITAL HERPES; HEADACHE; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEXUALLY TRANSMITTED DISEASE; VACCINE PRODUCTION;

EID: 16944362192     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514103     Document Type: Article

References (14)

1. Corcy L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983;98:973-83.
2. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A scroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989;321:7-12.
3. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes. A placebo-controlled doubled-blind trial of oral acyclovir. N Engl J Med 1984;310:1545-50.
4. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-6.
5. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir A controlled trial. JAMA 1984;251:2103-7.
6. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996;156:1729-39.
7. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind, multicenter trial. JAMA 1996;276:44-9.
8. Krause PR, Straus SE. The treatment, management and prevention of genital herpes. In: Stanberry LR, ed. Genital and neonatal herpes. New York: J Wiley & Sons, 1996:139-78.
9. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins protects mice against acute virus-induced neurological disease. Infect Immun 1981;34:192-9.
10. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982;37:1132-7.
11. Zarling JM, Moran PA, Burke RL, Pachl C, Berman PW, Lasky LA. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. J Immunol 1986;136:4669-73.
12. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155:914-20.
13. Stanberry LR, Myers MG, Stephanopoulos D, Burke RL. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J Gen Virol 1989;70:3177-85.
14. Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1988;157:897-902.